US-based PerkinElmer has introduced new Solaris quantitative optical molecular imaging system for use in small and large animal studies.


The new system has been designed to help in advancing drug discovery and translational research to develop and validate molecular-guided surgical research protocols.

PerkinElmer life sciences and technology president Brian Kim said the Solaris system is firm’s latest breakthrough translational quantitative imaging solution designed to facilitate disease studies and advance next-generation, molecular-level surgical support research.

"Translational drug discovery validation in large animal models enhances toxicity and efficacy predictability in humans and provides critical knowledge for drug development programs," Kim added.

The system, which has been developed for ambient lighting conditions found in preclinical surgical research suites, can dynamically use a wide range of fluorescent probes, providing flexibility for translational researchers when targeting diseases.

The system can be used in research applications such as drug efficacy, drug safety, measurement of real-time biological therapeutic responses and advanced molecular-guided surgery applications, including surgical tumor margin determination in live animal models.

The company will exhibit the Solaris system at the World Molecular Imaging Congress (WMIC) 2014, which will start on 17 September in Seoul, South Korea.

In addition, the company will showcase G8 bench-top PET/CT translational imaging system, Quantum GX microCT in vivo imaging system and selected additional optical in vivo imaging systems.

Image: PerkinElmer’s Solaris quantitative optical molecular imaging system. Photo: courtesy of Business Wire.